Augustin M, Thaci D, Eyerich K, et al. - In this post hoc analysis of two phase III randomized controlled trials, FIXTURE and CLEAR, researchers determined the stability of response to secukinumab [a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A], changes in effectiveness were evaluated in individual patients. For this investigation, participants received secukinumab 300 mg (FIXTURE and CLEAR), etanercept 50 mg (FIXTURE) or ustekinumab 45 or 90 mg (CLEAR) over 52 weeks. According to results, secukinumab efficacy was stable in most patients over 52 weeks of treatment, and continued treatment with secukinumab resulted in a recovery of efficacy in some patients after loss. Persistent loss of response was uncommon in this analysis. The likelihood of loss of efficacy may be affected by patient factors like body weight.